1 / 37

Case Conference

Case Conference. Block 8B Class 2011 Sylim , Tabula, Taldtad , Taleon Tampo , Tanyu, Tiongson , Torio. Primary Survey. MB, 19 year old female student from Cavite Acetaminophen ingestion BP = 110/70 HR = 90 RR = 20 GCS 15. History of Present Illness.

baris
Download Presentation

Case Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case Conference Block 8B Class 2011 Sylim, Tabula, Taldtad, Taleon Tampo, Tanyu, Tiongson, Torio

  2. Primary Survey • MB, 19 year old female student from Cavite • Acetaminophen ingestion • BP = 110/70 • HR = 90 • RR = 20 • GCS 15

  3. History of Present Illness • Four hours prior to consult, the patient intentionally took in 18 tablets of acetaminophen 500 mg per tablet after repeated arguments with her mother over her allowance. • Patient then experienced nausea, 1 episode of vomiting, and headache.

  4. History of Present Illness • There were no seizures, diaphoresis, loss of consciousness, nor headache. • Patient appeared flushed and had clammy extremities. • She was rushed to a private hospita; and referred to PGH.

  5. Review of Systems • (+) epigastric pain • (-) headache • (-) loss of consciousness • (-) bleeding • (-) jaundince • (-) urinary changes

  6. Past Medical History • Non-asthmatic, no known allergies • No previous hospitalizations • No previous surgeries

  7. Family Medical History • (+) hypertension – mother, father • (+) kidney problem – mother • (+) heart problem – mother, father

  8. OB History • G0 • LMP: January 13, 2010 • Menarche at 11 • 5-6 days duration, 3 ppd, regular monthly intervals • Denies OCP use

  9. Personal and Social History • Smoker for 5 years consuming 5 sticks per day; note of increased frequency and number of sticks consumed wihin the month • Occasional alcohol drinker; history of alchol binge 1 day PTA consuming beer, gin, and vodka • Denies illicit drug use

  10. Physical Examination • Awake, conversant • BP 110/70, HR 88, RR 20 • Anictericsclerae, pink palpebralconjuctivae, no NVE, no ANM • ECE, CBS • AP, DHS, NRRR, no murmurs • Flabby, soft, NABS, (+) direct tenderness epigastric area • FEP, PNB. No edema, no cyanosis

  11. Initial Assessment • Acetaminophen ingestion, non-accidental, mild • t/c adjustment disorder

  12. Initial Diagnostics • CBC • RBS, Crea, Na, K, Cl • PT/PTT • Urinalysis • Pregnancy test • ABG • 12 lead ECG • Chest x-ray

  13. Therapeutics • O2 6 lpm via nasal cannula • Diet: NPO • IVF: D5NSS 1 L x 8 hours • Famotidine 40 mg IV • N-acetylcysteine antidote

  14. Porcedures • NGT inserted for gastric lavage

  15. Referrals • Toxicology • Psychiatry • General Medicine

  16. Treatment • For gastric lavage with activated charcoal 100 mg in 200 mL water then NaSO4 15 g in 100 mL water • For serum paracetamol assay • Urine tox screening for paracetamol

  17. Treatment • NAC 200 mg/dL • Phase 1 150 mg/kg in 200 mL D5W x 1 hour (7.5 g) • Phase 2 50 mg/kg in 500 mL D5W x 4 hours (2-5 g) • Phase 3 100 mg in 1000 mL D5W x 16 hours (5 g)

  18. Laboratory Results (1/15) • PT 11.9/11.3/>1.0/1.09 • PTT 36.2/37/0 • ABG: pH 7.394, pCO2 34.8, pO2 116.3, HCO3 21.2, O2 sat 98.1, BE -2.4 mmol/L, TCO2 22.3, SBC 22.5 • CBC: Hgb 130, Hct 0.359, WBC 6.1, PC 379, neut 0.487, lymph 0.36, mono 0.138, eosino 0.009, baso 0.006

  19. Laboratory Results (1/15) • Glucose 6.09, BUN 2.51, Crea 73, Na 137, K 3.7, Cl 103

  20. Pathophysiology

  21. Maximum therapeutic dose: - 4g in adults - 90mg/kg in children Toxicity is with single ingestion of 150 mg/kg or ~7-10 g (adult)

  22. -Metabolism is primarily hepatic -Liver metabolizes more than 90% of dosage to sulfate and glucuronide conjugates, which are water soluble and are then eliminated in the urine -Two percent of an acetaminophen dose is excreted unchanged by the kidneys -Remaining acetaminophen is metabolized by CYP450 system to form a reactive, highly toxic metabolite known as N -acetyl-benzoquinoneimine (NAPQI)\ -Glutathione binds NAPQI, enabling the excretion of nontoxic mercapturate conjugates in the urine

  23. -in excessive NAPQI formation, or reduction in glutathione stores, NAPQI covalently binds to the lipid bilayer of hepatocytes, causing hepatic centrilobular necrosis.

  24. Four Clinical Stages Stage 1 (0.5-24 h postingestion) -Asymptomatic or with nonspecific signs like anorexia, nausea, vomiting, malaise, and diaphoresis.  -If CNS involvement and/or severe metabolic acidosis (elevated anion gap) are present, consider co-ingestants. -Serum studies are within normal limits. About 12 hours post-ingestion, subclinical elevation of serum liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) occurs.

  25. Stage 2 (24-72 h postingestion) -Stage 1 symptoms less evident and/or resolved. -Present with pain and tenderness in the RUQ -Hepatomegaly can be present. Some may have oliguria -Elevated ALT and AST levels, prothrombin (PT) times, and bilirubin values. Renal function abnormalities (eg, BUN, creatinine) may also be present.

  26. Stage 3 (72-120 h postingestion) -Stage 1 symptoms reappear along with signs of hepatic failure with jaundice, hypoglycemia, bleeding, or encephalopathy. -Severe toxicity evident on serum studies. Lactic acidosis, prolonged PT or INR, markedly elevated ALT and AST (>10,000 IU/L), elevated total bilirubin level of more than 4 mg/dL (primarily indirect) and hyperammonemia -Hepatic centrilobular necrosis is diagnosed on liver biopsy -Renal involvement from acute tubular necrosis is evident with abnormal renal function studies, proteinuria, hematuria and granular casts on urinalysis -Death is most common during this stage, with multiorganfailure as the primary cause.

  27. Stage 4 (5-14 d postingestion) -this stage can last as long as 21 days. -either a complete recovery of liver function or death -period to normalization may take several weeks for patients who recover -Acetaminophen-induced hepatotoxicity does not cause chronic hepatic dysfunction.

  28. Work-up Acetaminophen serum concentration Transaminase levels Measures of hepatic function Electrolytes and creatinine Beta-hcg for women childbearing age BT and crossmatch Urinalysis ABG UTZ/CT ECG

  29. Treatment

  30. Approach to a patient of Acetaminophen Ingestion • Initial Assessment • Gastric Decontamination • Acetylcysteine Need Assessment • Acetylcysteine Administration

  31. Approach to a patient of Acetaminophen Ingestion • Initial Assessment • Determination of quantity and dosage form • Determination of the possibility of the ingestion of other substances or drugs • Determination of serum acetaminophen levels • If any information is unknown, serum levels should be determined and acetylcysteine should be administered

  32. Approach to a patient of Acetaminophen Ingestion • Gastric Decontamination • Activated charcoal reduces peak serum levels, decreases 4-hour acetaminophen and lowers the need for acetylcysteine treatment • Activated charcoal may be given postingestion period, especially if multiple drugs are suspected • Data regarding efficacy of activated charcoal after 2 hours postingestion are limited

  33. Approach to a patient of Acetaminophen Ingestion • Acetylcysteine Need Assessment • Ideally serum acetaminophen is measured 4 hours postingestion, or if 4 hours have passed, immediately thereafter • If ingestion is over a period of time, time of initial ingestion is used for Rumack-Matthew nomogram • If blood cannot be obtained, the dose is assumed to be toxic and treatment is given

  34. Approach to a patient of Acetaminophen Ingestion • Acetylcysteine Administration • If patient presented within 4 hours postingestion, treatment is delayed until serum levels are determined (however treatment should not be delayed beyond 8 hours postingestion) • If patient presented beyond 8 hours postingestion, treatment is given immediately • If patient presented 24 hours postingestion, AST and ALT are determined(treatment is beneficial if levels are elevated; if not, treatment is unnecessary)

  35. -Supportive therapy, including IV fluids, oxygen, cardiac monitor -Gastric decontamination (oral activated charcoal) -Administer N-acetylcysteine if indicated -early administration (within 8 hours) is ~100% hepatoprotective 1. PO: 140 mg/kg loading dose; maintenance dose of 70 mg/kg q4 x17 doses 2. Continuous IV: (total treatment time 21 h) Acute (8-10 h after ingestion) in patients >40 kg: >Loading dose: 150 mg/kg IV infused over 15 min (dilute in 200 mL D5W) follow with maintenance doses >First maintenance dose: 50 mg/kg IV infused over 4 h (dilute in 500 mL D5W), followed with second maintenance dose >Second maintenance dose: 100 mg/kg IV infused over 16 h (dilute in 1000 mL D5W)

  36. 3. Intermittent IV administration (total treatment 48 h)>Loading dose: 140 mg/kg IV infused over 1 h (dilute in 500 mL D5W), followed with maintenance dose >Maintenance dose: 70 mg/kg IV q4h for at least 12 doses (dilute each dose in 250mL of D5Wand infuse over minimum 1h) -Antiemetics -metoclopramide, ondansetron

More Related